유전자 편집 완벽 가이드.
메뉴
배우기 뉴스 아틀라스에 질문하기
둘러보기 기술들 질환 치료법들 임상시험 기업 과학자들 유전자 연구 기관
의학을 넘어서 농업 윤리 투자 세계 지도
배우기 & 도구 여기서 시작하세요 용어집 A–Z 기술 비교 타임라인 목록 & 순위 AI 에이전트 ★ 저장됨 API
소개 소개 방법론 데이터 출처 편집 방침 문의 면책 조항

🧭 안내 보기
유전학이 처음이신가요? 둘러보시는 동안 모든 용어를 쉬운 말로 설명해 드립니다. 도움말이 내장된 동일한 페이지입니다.

⚡ 전문가 견해
생물학은 이미 알고 계시죠. 내용만 — 깔끔하고 간결하게, 추가 설명 없이. 기본 보기입니다.

인터페이스 언어
라이트 모드

Intermediate

Viral vectors

Modified viruses used as delivery vehicles — very good at getting inside cells, which is exactly what they evolved to do.

짧은 답변

Viruses spend their existence solving one problem: getting genetic material into cells. So we take a virus, remove the genes that make it dangerous and let it replicate, and put our cargo in instead. The main ones are AAV, which does not integrate into the genome, and lentivirus, which does.

Adeno-associated virus delivers cargo that persists mainly as an episome, giving durable expression in non-dividing tissue but diluting out in dividing cells; capacity is about 4.7 kb and pre-existing neutralising antibodies exclude many patients. Lentivirus integrates into the genome, giving durable expression through division at the cost of insertional-mutagenesis risk. Both provoke immune responses, and high systemic AAV doses have caused severe and fatal hepatotoxicity.

Where the risk actually lies

AAV is often described as safe because it does not integrate and causes little disease naturally. At the doses needed to reach a large tissue like muscle, that reassurance breaks down: severe liver injury, complement activation and deaths have occurred in gene-therapy trials at high systemic doses. This is a dose problem, not a virus problem, and it is the main reason muscle indications remain so difficult.

ImportantDeaths have occurred in AAV gene-therapy trials at high systemic doses. This is a well-documented risk, not a theoretical one.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.